Recurrent Plasma Cell Myeloma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1384 more
2022-01-13
Jan 13, 2022
A
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
2022-01-02
Jan 2, 2022
C
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Duarte, California
    City of Hope Medical Center
2022-01-10
Jan 10, 2022
A
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Daratumumab
  • +2 more
  • Peoria, Illinois
  • +10 more
2022-01-05
Jan 5, 2022
A
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Des Moines, Iowa
  • +7 more
2022-01-05
Jan 5, 2022
N
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Recruiting
  • Plasmacytoma
  • +2 more
  • Sacramento, California
  • +5 more
2022-01-05
Jan 5, 2022
E
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
  • +3 more
2022-01-05
Jan 5, 2022
N
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Recruiting
  • Lymphoma
  • +6 more
  • Cytology Specimen Collection Procedure
  • Birmingham, Alabama
  • +139 more
2022-01-04
Jan 4, 2022
M
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • t(11;14)
  • Ann Arbor, Michigan
  • +2 more
2021-12-22
Dec 22, 2021
M
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
2021-12-22
Dec 22, 2021
U
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
Recruiting
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +11 more
  • Fluorine F 18-fluoroazomycin Arabinoside
  • Positron Emission Tomography
  • San Francisco, California
    University of California, San Francisco
2021-12-17
Dec 17, 2021
O
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-12-22
Dec 22, 2021
V
Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Active, not recruiting
  • Hodgkin's Lymphoma
  • +17 more
  • mycophenolate mofetil
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University/Massey Cancer Center
2021-12-21
Dec 21, 2021
U
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-12-09
Dec 9, 2021
E
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Atlanta, Georgia
  • +1 more
2021-12-07
Dec 7, 2021
A
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-11-30
Nov 30, 2021
M
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma - 2021
Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic
2021-12-01
Dec 1, 2021
N
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
  • Anemia
  • +2 more
  • Atlanta, Georgia
  • +2 more
2021-11-24
Nov 24, 2021
F
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Not yet recruiting
  • Plasma Cell Myeloma
  • +2 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-11-15
Nov 15, 2021
M
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
Active, not recruiting
  • Plasma Cell Leukemia
  • +3 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-18
Nov 18, 2021
U
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
2021-11-16
Nov 16, 2021
C
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • CS1-CAR T Therapy
  • +3 more
  • Duarte, California
    City of Hope Medical Center
2021-11-15
Nov 15, 2021
M
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-11-01
Nov 1, 2021
U
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Recruiting
  • Plasma Cell Leukemia
  • +2 more
  • Biospecimen Collection
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-10-18
Oct 18, 2021
M
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Scottsdale, Arizona
  • +2 more
2021-10-18
Oct 18, 2021